Compugen (NASDAQ: CGEN)
Compugen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Compugen Company Info
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
News & Analysis
Why Compugen Shares Are Up Today
The company released its fourth-quarter and full-year results after the bell Monday.
Why Compugen Stock Got Slammed Today
Clinical-stage biotechs are particularly susceptible to shifts in analyst sentiment.
Why Shares of Compugen Rose on Thursday
The clinical-stage biotech retreated a bit from one of its biggest days in a while.
Why Shares of Compugen Rose 16.5% on Wednesday
Market factors and a company announcement helped the stock climb.
Why Shares of Compugen Jumped 17.86% on Thursday
The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies.
Why Compugen Stock Crumbled Today
Investors indicated their displeasure with the company's recent fundamentals.
Why Shares of Compugen Jumped 9.27% on Tuesday
The stock's rise came after the company announced when third-quarter earnings will be presented.
Why Compugen Stock Got Slammed Today
A price cut from an analyst had some traders hitting the sell button.
Valuation
Earnings Transcripts
Compugen Ltd (CGEN) Q3 2021 Earnings Call Transcript
CGEN earnings call for the period ending September 30, 2021.
Compugen Ltd (CGEN) Q2 2021 Earnings Call Transcript
CGEN earnings call for the period ending June 30, 2021.
Compugen Ltd. (CGEN) Q1 2021 Earnings Call Transcript
CGEN earnings call for the period ending March 31, 2021.
Compugen Ltd. (CGEN) Q4 2020 Earnings Call Transcript
CGEN earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.